A PK/PD model for the evaluation of clinical rifaximin dosage for the treatment of dairy cow mastitis induced by Escherichia coli

[1]  Yuan Liu,et al.  PK/PD integration and pharmacodynamic cutoff of cefquinome against cow mastitis due to Escherichia coli. , 2021, Journal of veterinary pharmacology and therapeutics.

[2]  Xiaojie Chen,et al.  PK/PD Modeling to Assess Rifaximin Clinical Dosage in a Mouse Model of Staphylococcus aureus-Induced Mastitis , 2021, Frontiers in Veterinary Science.

[3]  A. Bandoni,et al.  Melaleuca armillaris Essential Oil in Combination With Rifaximin Against Staphylococcus aureus Isolated of Dairy Cows , 2020, Frontiers in Veterinary Science.

[4]  L. Cariddi,et al.  Characterization of an Enterococcus faecium strain in a murine mastitis model , 2019, Journal of applied microbiology.

[5]  Xiaoyu Li,et al.  Evaluation of phage therapy in the treatment of Staphylococcus aureus-induced mastitis in mice , 2019, Folia Microbiologica.

[6]  Guo-chun Ding,et al.  Impact of direct application of biogas slurry and residue in fields: In situ analysis of antibiotic resistance genes from pig manure to fields. , 2018, Journal of hazardous materials.

[7]  Jia Hua Cheng,et al.  Cloning, Expression, and Immunogenicity of Fimbrial-F17A Subunit Vaccine against Escherichia coli Isolated from Bovine Mastitis , 2017, BioMed research international.

[8]  Jian Sun,et al.  Efficacy of Cefquinome against Escherichia coli Environmental Mastitis Assessed by Pharmacokinetic and Pharmacodynamic Integration in Lactating Mouse Model , 2017, Front. Microbiol..

[9]  Jian Sun,et al.  Dose Assessment of Cefquinome by Pharmacokinetic/Pharmacodynamic Modeling in Mouse Model of Staphylococcus aureus Mastitis , 2016, Front. Microbiol..

[10]  Yahong Liu,et al.  In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes , 2015, Antimicrobial Agents and Chemotherapy.

[11]  Alicia Rodríguez-Gascón,et al.  Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[12]  M. Pimentel,et al.  In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. , 2014, International journal of antimicrobial agents.

[13]  K. Breyne,et al.  Short communication: Antimicrobial efficacy of intramammary treatment with a novel biphenomycin compound against Staphylococcus aureus, Streptococcus uberis, and Escherichia coli-induced mouse mastitis. , 2013, Journal of dairy science.

[14]  C. Hudson,et al.  Rate of transmission: a major determinant of the cost of clinical mastitis. , 2013, Journal of dairy science.

[15]  Rahul Modak,et al.  Histone H3K14 and H4K8 hyperacetylation is associated with Escherichia coli-induced mastitis in mice , 2012, Epigenetics.

[16]  Laura J V Piddock,et al.  The crisis of no new antibiotics--what is the way forward? , 2012, The Lancet. Infectious diseases.

[17]  Suzanna Gim,et al.  Rifaximin: new therapeutic indication and future directions. , 2011, Clinical therapeutics.

[18]  Henk Hogeveen,et al.  Economic aspects of mastitis: New developments , 2011, New Zealand veterinary journal.

[19]  T. Vanden Berghe,et al.  Inflammatory mediators in Escherichia coli-induced mastitis in mice. , 2008, Comparative immunology, microbiology and infectious diseases.

[20]  A. Marchese,et al.  Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations , 2008, Journal of chemotherapy.

[21]  Steffen Jung,et al.  Toll‐like receptor 4 is needed to restrict the invasion of Escherichia coli P4 into mammary gland epithelial cells in a murine model of acute mastitis , 2007, Cellular microbiology.

[22]  M. J. Pons,et al.  In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. , 2007, Diagnostic microbiology and infectious disease.

[23]  H. Dupont,et al.  Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  É. Brouillette,et al.  The pathogenesis and control of Staphylococcus aureus-induced mastitis: study models in the mouse. , 2005, Microbes and infection.

[25]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[26]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[27]  P. Maincent,et al.  Bovine mastitis and intramammary drug delivery: review and perspectives. , 2001, Advanced drug delivery reviews.